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Abstract
Background: A better understanding of hypoglycaemia risk when insulin is used in combination with one or more oral antidiabetes agents 
may assist in the treatment decision-making process for the clinician and address concerns regarding hypoglycaemia when initiating or 
intensifying insulin therapy. The objective of this study was to analyse efficacy and hypoglycaemia outcomes in people with type 2 diabetes 
receiving insulin glargine (IG) with metformin (MET), sulphonylurea (SU) or MET+SU. Methods: Patient-level data were pooled from 15 
randomised, treat-to-target trials (fasting plasma glucose [FPG] targets <5.6 mmol/l) with a duration ≥24 weeks. Efficacy outcomes included 
glycated haemoglobin (HbA1c), FPG and HbA1c target achievement. Overall hypoglycaemia events were assessed by a confirmed PG value 
of <3.9, <3.1 and <2.8 mmol/l or assistance required; daytime, nocturnal (00:01–05:59 AM); and severe (assistance required or with confirmed 
PG <2.0 mmol/l). Results: Overall, 2,837 IG patients were analysed, with either MET (634), SU (906) or MET+SU (1,297) as background oral 
antidiabetes agents. Endpoint HbA1c in IG+MET and IG+MET+SU-treated patients was significantly lower than in IG+SU-treated patients (adjusted 
difference –0.32 %; p=0.0001 and –0.33 %; p=0.0002, respectively). Fewer patients achieved endpoint HbA1c <7.0 % with IG+SU (32 %) versus 
IG+MET (57 %) or IG+MET+SU (49 %). IG+SU and IG+MET+SU led to significant increases in overall, daytime and nocturnal hypoglycaemia 
versus IG+MET; severe hypoglycaemia was rare. Weight gain was lowest in IG+MET patients (adjusted difference –1.51 kg versus IG+SU; 
p<0.0001; –0.78 kg versus IG+MET+SU; p=0.0037) despite higher insulin doses (0.51 U/kg versus 0.43 and 0.42 U/kg, respectively). Conclusions: 
Better glycaemic goal achievement and reduced risk of hypoglycaemia and weight gain were observed with IG+MET versus IG+SU and 
IG+MET+SU, albeit with an increased insulin dose requirement. 
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Maintaining appropriate glycaemic control in type 2 diabetes can 
prevent or delay the development and progression of diabetes 
complications.1–3 Initial pharmacological treatment usually begins with 
metformin (MET), with a second agent being added once monotherapy 
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is insufficient to provide adequate glycaemic control.3 Over time, a 
substantial proportion of patients will ultimately require insulin therapy 
to maintain glucose control.3–5 MET is usually maintained and whether 
sulphonylurea (SU) should be discontinued or maintained at the start of 
insulin therapy is an unresolved matter.6
When selecting glucose-lowering agents to achieve glycaemic targets, 
several factors should be taken into consideration, including the glucose-
lowering potential of the agent, the risk of hypoglycaemia, weight gain, 
tolerability and costs. Hypoglycaemia can influence well-being, quality 
of life and cause anxiety.7 Fear of hypoglycaemia may represent a barrier 
to some physicians who might be reluctant to prescribe insulin8 or delay 
initiating insulin.9,10 It is also a commonly quoted reason for patient 
reluctance to accept insulin11 or intensify their insulin regimen.12,13
The definition of hypoglycaemia in clinical trials is based on symptoms 
(including severity), blood glucose levels and the timing of the event. 
In symptomatic events, the patient displays one or more symptoms of 
hypoglycaemia; in confirmed events, a ‘low’ blood glucose measurement 
is documented; and severe events usually require ‘third-party assistance’ 
with or without blood glucose measurements and prompt recovery on 
countermeasures.14 In addition, hypoglycaemic events can be classified 
as daytime or nocturnal events. Reporting of data on hypoglycaemia 
across randomised controlled trials investigating the use of basal insulin 
analogues in type 2 diabetes has not been standardised, with various 
definitions and blood glucose cutoffs utilised within the literature.15 In 
addition, the collection of hypoglycaemia data is often incomplete and 
relies on patient reporting and transcription of events. This can make the 
interpretation of data on hypoglycaemia problematic.16
The use of standardised endpoints to define clinical hypoglycaemia 
could enable physicians to make informed treatment decisions based 
on the risks and benefits of therapy. A better understanding of the 
hypoglycaemia risk when insulin is used in combination with one or more 
glucose-lowering agents may further inform the treatment decision-
making process for the clinician, and address concerns regarding 
hypoglycaemia when initiating or intensifying insulin therapy.
The aim of this pooled analysis of patient-level data was to investigate 
efficacy (glycated haemoglobin [HbA1c], responder rate, fasting plasma 
glucose [FPG]) and safety outcomes (hypoglycaemia, weight) of insulin-
naïve people with type 2 diabetes included in treat-to-target randomised 
Table 1: Summary of 15 Treat-to-target Trials Included in the Pooled Analyses
Study Phase Treatmenta Number of Treatment Period Goal Blood Glucose for Insulin Titration
   Patients (Weeks)  Insulin Glargine (mmol/l) Schedule
IG+MET Studies    
LANTU_C_02761 (EASIE)1 IIIb/IV IG+MET vs. SITA+MET 515 24 ≤5.6 Twice weekly 
4020b2 IIIb IG+SU or MET vs.  389 24 extended ≥3.9 and ≤5.6 (weeks 0–24) Weekly  
  PIO+SU or MET  to 48 ≥3.9 and ≤5.2 (weeks 25–48)   
4022b3 IIIb IG+SU or MET vs. 337 24 extended ≥4.0 and ≤5.6 (weeks 0–24) Weekly  
  TZD+SU+MET  to 48 ≥3.9 and ≤5.2 (weeks 25–48)  
LANTU_C_00579 (L2T3)c4 IV IG+OADs vs.  973 24 ≤5.6 Every 2 days  
  DET+OADs 
3502 (INSIGHT)b,c5 IIIb IG+current OADs vs. current OADs 405 24 ≤5.6 Daily 
IG+SU Studies   
40016 IIIb IG+GLI vs.  695 24 ≤5.6 Weekly  
  NPH insulin+GLI 
40097 IIIb Morning vs. bedtime 624 24 ≤5.6 Weekly  
  IG+morning GLI  
40138 IIIb IG+GLI vs.  481 24 ≤5.6 Weekly  
  NPH insulin+GLI 
IG+MET+SU Studies   
4002 (TTT)9 IIIb IG+OADs vs. NPH insulin+OADs 764 24 ≤5.6 Weekly
4014 (TRIPLE)10 IIIb IG+SU+MET vs.  219 24 ≤5.6 Weekly  
  ROS+SU+MET 
402111 IIIb IG+SU+MET vs.  212 24 ≤5.6 Weekly  
  LIS 75/25+SU+MET 
4027 (LAPTOP)12 IIIb IG+GLI+MET vs.  371 24 ≤5.6 Weekly for first 8  
  premixed NPH insulin 30/70    weeks, then at   
      2-week intervals
4040 (APOLLO)13 IV IG+OADs vs. LIS+OADs 415 44 ≤5.6 Weekly 
4041 (INITIATE)14 IV IG with group education+  121 24 4.0–5.5 Self-titration, then  
  OADs vs. IG with individual    investigator-reviewed 
  education+OADs    at each visit
4042 (TULIP)15 IV IG+OADs vs. hygienic and  215 40 3.9–5.6 Every 2 days  
  dietary measures+OADs 
aFrom the insulin glargine (IG) arms of each of the considered studies, the pool for analysis was composed of patients treated with IG+metformin (MET), IG+sulphonylurea (SU) 
or IG+MET+SU. bAlso included in the analysis of IG+SU studies. cAlso included in the analysis of IG+MET+SU studies. DET = insulin detemir; GLI = glimepiride; LIS = insulin lispro; 
NPH = neutral protamine hagedorn (intermediate-acting insulin); OAD = oral antidiabetic drugs; PIO = pioglitazone; ROS = rosiglitazone; SITA = sitagliptin; TZD = thiazolidinedione.
1. Aschner P, et al., Lancet, 2012;379:2262–9; 2. Meneghini LF, et al., Endocr Pract, 2010;16:588–99; 3. HOE901_4022 data on file [NCT00046462]. Available at: http://clinicaltrials.
gov/ct2/show/NCT00046462 (accessed 25 March 2013); 4. Swinnen SG, et al., Diabetes Care, 2010;33:1176–8; 5. Gerstein HC, et al., Diabet Med, 2006;23:736–42; 6. Fritsche A, 
et al., Ann Intern Med, 2003;138:952–9; 7. Standl E, et al., Diabetes Care, 2005;28:419–20; 8. Eliaschewitz FG, et al., Arch Med Res, 2006;37:495–501; 9. Riddle MC, et al., Diabetes Care, 
2003;26:3080–86; 10. Rosenstock J, et al., Diabetes Care, 2006;29:554–9; 11. HOE901_4021 data on file [NCT01336751. Available at: http://clinicaltrials.gov/ct2/show/NCT01336751 
(accessed 25 March 2013); 12. Janka HU, et al., Diabetes Care, 2005;28:254–9; 13. Bretzel RG, et al., Lancet, 2008;371:1073–84; 14. Yki-Järvinen H, et al., Diabetes Care, 2007;30:1364–9; 
15. Blicklé JF, et al., Diabetes Obes Metab, 2009;11:379–86.
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controlled studies who received insulin glargine (IG) once-daily at bedtime 
in combination with different oral antidiabetes drugs (OADs). We compared 
the profile and outcomes of patients treated with IG and MET (IG+MET) with 
those treated with IG and a SU (IG+SU) and those treated with IG+MET+SU.
Methods
Study Selection and Population
Eligibility criteria were prospective, randomised, controlled, treat-to-
target trials with protocol-driven titration algorithms targeting FPG levels 
<5.6 mmol/l (<100 mg/dl) with a duration ≥24 weeks. Studies enrolled 
insulin-naïve adult patients with type 2 diabetes, who all initiated IG in 
combination with their current OADs according to the study protocols. 
For the analysis of IG+MET, studies had to include an arm or predefined 
subpopulation that was treated with only IG+MET. Similarly, for the 
analyses of IG+SU and IG+MET+SU, the studies had to include an arm 
or predefined subpopulation who received only these treatments 
for the entire study period. Comparator controls included either OAD 
combination therapy, other insulin treatment with OADs or lifestyle 
interventions only. The analysis considered only studies conducted by 
the manufacturer of IG (i.e., Sanofi or its predecessor companies) and 
those in accordance with Good Clinical Practice (GCP) guidelines where 
detailed information based on individual patient-level data for efficacy 
and hypoglycaemia were available.
Overall, 15 studies fulfilled all of the inclusion criteria, of which 13 
have been published (see Table 1). Two studies were eligible for both 
the analysis of IG+MET and IG+MET+SU, two studies for the analysis 
of IG+MET and IG+SU and one study for the analysis of IG+SU and 
IG+MET+SU. The analysis of IG+MET included patients previously treated 
with MET who were subsequently treated with IG+MET for the 24-
week treatment period. Moreover, patients who received antidiabetes 
treatments other than IG+MET from the point of randomisation up to 
and including the day after the end of the 24-week treatment period, or 
who did not receive both IG and MET were excluded from the analysis 
pool. Similarly, the analyses of IG+SU and IG+MET+SU only included 
patients who were previously treated with these OAD combinations, 
and those who were subsequently treated with only these OADs in 
combination with IG during the randomised treatment period.
Efficacy Outcomes
Efficacy was evaluated using the following outcomes: endpoint and 
change from baseline to endpoint in HbA1c level, the percentage of 
patients achieving an HbA1c level <7.0  % at week 24 and endpoint 
and the change from baseline to endpoint in FPG level. Endpoint was 
defined as the last on-treatment measurement up to and including 
week 24 plus 14 days for HbA1c and plus 1 day for FPG.
Hypoglycaemia Outcomes
Numbers of confirmed hypoglycaemic events were determined by using 
several PG cutoffs : PG <3.9 mmol/l (<70 mg/dl), <3.1 mmol/l (<56 mg/
dl) and <2.8  mmol/l (<50  mg/dl), respectively. These categories were 
also analysed by time of occurrence during the day: at any time of 
the day (defined as PG-confirmed events over 24 hours), daytime (PG-
confirmed events occurring between 06:00 and midnight) and nocturnal 
(PG-confirmed events between 00:01 and 05:59). In addition, a severe 
hypoglycaemic event was assessed using two definitions irrespective of 
time of occurrence: events requiring third-party assistance) and events 
requiring third-party assistance with documented PG <2.0  mmol/l 
(<36 mg/dl). 
Overall hypoglycaemia occurring at any time of the day included PG-
confirmed events or severe events requiring third-party assistance 
(without a documented PG value). Daytime and nocturnal hypoglycaemia 
analysis excluded any severe events. 
Composite Outcomes and Body Weight
The percentage of patients achieving an HbA1c level <7.0 % at week 24 
without overall or nocturnal hypoglycaemia with PG <3.9 mmol/l and 
Table 3: Efficacy Outcomes and Insulin  
Dose at Endpoint
 IG+MET IG+SU IG+MET+SU Pooled
n 593 867 1,268 2,728
Week 24 HbA1c (%) 7.0±1.0 7.6±1.2 7.1±0.9 7.2±1.0
Change in HbA1c from  –1.7±1.2 –1.4±1.2 –1.6±1.0 –1.6±1.2  
baseline to endpoint (%)
Patients with HbA1c <7.0 %  336 270 620 1,226  
at endpoint, n (%)a (56.8) (31.5) (49.3) (45.3)
n 583 884 1,252 2,719
Week 24 FPG (mmol/l) 6.2±2.0 6.8±2.2 6.7±2.1 6.6±2.2
Change in FPG from –4.1±3.2 –4.6±3.6 –4.0±3.2 –4.2±3.4  
baseline to endpoint (mmol/l)
n 634 906 1,297 2,837
Week 24 insulin dose (U/kg) 0.51±0.27 0.43±0.24 0.42±0.25 0.44±0.26
Change in insulin dose from 0.35±0.28 0.23±0.23 0.29±0.25 0.28±0.25 
baseline to endpoint (U/kg)
Values are mean ± standard deviation unless otherwise noted. aLimited to patients with 
baseline glycated haemoglobin (HbA1c) ≥7.0 %. FPG = fasting plasma glucose; IG = insulin 
glargine; MET = metformin; SU = sulphonylurea.
Table 2: Demographics and Baseline Characteristics of Study Population
      Comparison
 IG+MET IG+SU IG+MET+SU Pooled IG+MET vs. IG+MET vs.  IG+SU vs.
     IG+SU IG+MET+SU IG+MET+SU
     p value p value p value
n 634 906 1,297 2,837
Age, years 54.7±9.6 59.1±10.2 58.2±9.3 57.7±9.8 <0.0001 <0.0001 0.03
Male sex, n (%) 330 (52.1) 488 (53.9) 708 (54.6) 1,526 (53.8) 0.50 0.31 0.74
Type 2 diabetes duration, years 7.3±5.7 9.5±6.6 9.5±6.3 9.0±6.4 <0.0001 <0.0001 0.99
Weight, kg 88±19.7 82.2±18 88.9±17.4 86.6±18.4 <0.0001 0.29 <0.0001
BMI, kg/m2 31.5±5.8 29.1±5.2 31.2±5.0 30.6±5.3 <0.0001 0.25 <0.0001
HbA1c, %  8.7±1.1 9.0±1.1 8.7±1.0 8.8±1.1 <0.0001 0.11 <0.0001
FPG, mmol/l 10.5±3.2 11.4±3.2 10.7±2.9 10.9±3.1 <0.0001 0.10 <0.0001
Values are mean ± standard deviation unless otherwise noted. p values are from analysis of variance models including treatment group as a factor and for gender variable; 
p value is from a logistic model including treatment group as a factor. BMI = body mass index; FPG = fasting plasma glucose; HbA1c = glycated haemoglobin; IG = insulin glargine; 
MET = metformin; SU = sulphonylurea.
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<3.1 mmol/l over the treatment period are reported. Weight data were 
analysed for patients treated with IG+MET, IG+SU or IG+MET+SU.
Statistical and Analytical Procedures
Baseline and week 24 patient-level data for patients treated with 
IG+MET, IG+SU and IG+MET+SU were pooled and analysed from all 
patients who were randomised and who subsequently received ≥1 
dose of IG and the OADs as defined for the subpopulation of interest. 
Continuous efficacy endpoints of HbA1c, dose and weight at endpoint 
were analysed using generalised linear models with adjustments for 
OAD treatment group, study, duration of diabetes, body mass index 
(BMI), age and baseline value. For the outcome of achievement of HbA1c 
<7.0 % at endpoint, odds ratios (ORs) for pairs of OAD treatment groups 
were derived from a logistic model, adjusting for the same factors as in 
the continuous model.
All hypoglycaemic events experienced up to and including 1 day after 
the end of the treatment period (day of last dose or week 24, whichever 
came first) were considered for analysis. Hypoglycaemic events were 
summarised by categories using descriptive statistics, including the 
number and percentage of patients with ≥1 event (incidence), the 
total number of episodes and the annualised rate (events/patient–
year). The incidence and annualised rate of hypoglycaemic events for 
each OAD treatment group were estimated and analysed using logistic 
and negative binomial regression, respectively. In both cases, BMI and 
duration of diabetes were pre-specified factors and were included for 
all hypoglycaemia categories for which there were sufficient data. Other 
potential prognostic factors (including age, gender, HbA1c at baseline, 
OAD treatment group, study and interaction of duration of diabetes 
and OAD treatment group) were considered for inclusion in the model 
using univariate analyses and multivariate model selection and were 
retained in the final model as appropriate. A p value of ≤0.05 was 
considered to be statistically significant.
The cumulative number of hypoglycaemia events per patient over 
time (by study day) was also determined. The relationship between 
hypoglycaemia and glycaemic outcomes at study end was also 
investigated using binomial meta-regression techniques.17 Regression 
coefficients for HbA1c and FPG at endpoint were used to model event 
rates per patient–year for HbA1c and FPG values reported at endpoint.
Results
Patients
Out of the patients who were treated with IG, 44 patients were 
excluded from analysis as they did not receive any of the prespecified 
background OAD medication. Another 34 patients were also excluded 
from the analysis as they referred to four study sites that were non-
compliant to GCP guidelines. As a result, a total of 2,837 patients 
treated with IG were eligible for analysis according to OAD background 
medication: 634 patients treated with IG+MET, 906 patients treated 
with IG+SU and 1,297 patients treated with IG+MET+SU. Patients in the 
latter two treatment groups were significantly older (p<0.0001 for both; 
p=0.0302 for IG+SU versus IG+MET+SU) and had a longer duration of 
type 2 diabetes (p<0.0001 for both). In IG+SU-treated patients, baseline 
HbA1c and FPG levels were significantly higher (all p<0.0001), and 
weight and BMI significantly lower (all p<0.0001) compared with the 
other two treatment groups (see Table 2).
Efficacy
Efficacy outcomes are summarised in Table 3. The IG+MET and 
IG+MET+SU treatment groups had similar endpoint HbA1c levels 
(7.0  % and 7.1  %, respectively) and a similar change in HbA1c level 
Figure 1: Cumulative Numbers of Overall and Nocturnal Hypoglycaemia Events per Patient 
Over Time for IG+MET (A and D, Respectively), IG+SU (B and E, Respectively) and IG+MET+SU  
(C and F, Respectively) Treatment Groups
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from baseline to endpoint (–1.7 % and –1.6 %, respectively). Patients 
in the IG+SU treatment group had an endpoint HbA1c level of 7.6  % 
and a change in HbA1c level from baseline to endpoint of –1.4  %. In 
the adjusted model, taking into account baseline HbA1c, endpoint 
HbA1c levels in the IG+MET and IG+MET+SU treatment groups 
were significantly lower and change from baseline to endpoint HbA1c 
levels significantly higher than in the IG+SU treatment group (difference 
for both: –0.32 %, 95 % confidence interval [CI] –0.48 to –0.16; p=0.0001 
and –0.33  %; 95  % CI –0.51 to –0.16; p=0.0002, respectively). The 
proportion of patients with HbA1c <7.0 % at week 24 was 57 %, 32 % 
and 49  % in the IG+MET, IG+SU and IG+ MET+SU treatment groups, 
respectively. Patients in the IG+MET treatment group were significantly 
more likely to achieve an HbA1c <7.0 % at week 24 than patients in the 
IG+SU treatment group (OR 2.00, 95 % CI 1.29–3.12). For the comparison 
of HbA1c achievement between patients treated with IG+MET+SU 
versus IG+SU, the OR was 1.66, 95 % CI 0.99–2.80. Endpoint FPG levels 
were 6.2, 6.7 and 6.7 mmol/l in the IG+MET, IG+SU and IG+MET+SU 
treatment groups, respectively. In the adjusted model, taking into 
account baseline FPG, endpoint FPG level was significantly lower and 
change from baseline to endpoint in FPG level significantly higher 
in the IG+MET treatment group than in the IG+SU and IG+MET+SU 
treatment groups (difference for both: –0.82 mmol/l, 95 % CI –1.17 to 
–0.47; p<0.0001 and –0.53 mmol/l, 95 % CI –0.83 to –0.23; p=0.0005, 
respectively). The insulin dose at endpoint was 0.51, 0.43 and 0.42 U/kg 
in the IG+MET, IG+SU and IG+MET+SU treatment groups, respectively. 
In the adjusted model, insulin dose at endpoint was significantly 
greater in the IG+MET treatment group compared with the IG+MET+SU 
treatment group (difference in adjusted endpoint dose: 0.06 U/kg, 95 % 
CI 0.02–0.09; p=0.0026) and numerically greater compared with the 
IG+SU group (0.01 U/kg, 95 % CI -0.03 to 0.06; p=0.5067).
Hypoglycaemia Rates and Incidence
Adjusted pooled incidences and event rates of overall, daytime, 
nocturnal and severe hypoglycaemia are shown in Table 4a and 4b. 
IG+SU and IG+MET+SU showed significant observed increases in overall, 
daytime and nocturnal hypoglycaemia rates (up to threefold compared 
with IG+MET). Daytime and nocturnal hypoglycaemia incidence was also 
increased in patients treated with IG+MET+SU and IG+SU compared with 
patients treated with IG+MET. Severe hypoglycaemia with IG was rare, with 
no significant differences observed in event rate or incidence between 
the three treatment groups (see Table 4a and 4b). A similar pattern of 
increased hypoglycaemia with IG+SU and IG+MET+SU compared with 
IG+MET was observed in the unadjusted data. The cumulative numbers 
of overall and nocturnal hypoglycaemia events per patient over time 
for the IG+MET, IG+SU and IG+MET+SU treatment groups are shown in 
Figure 1.
Binomial meta-regression revealed that, in patients treated with IG+MET, 
IG+SU and IG+MET+SU, both overall and nocturnal hypoglycaemia event 
rates increased in patients who achieved lower endpoint HbA1c levels 
Figure 2: Modelled Adjusted Overall (PG <3.9 mmol/l [A] and PG <3.1 mmol/l [B]) and Nocturnal 
(PG <3.9 mmol/l [C] and PG <3.1 mmol/l [D]) Hypoglycaemia Event Rates for HbA1c Values 
Reported at Endpoint
PG <3.9 mmol/l = <70 mg/dl; PG <3.1 mmol/l = <56 mg/dl. IG = insulin glargine; MET = metformin; PG = plasma glucose; SU = sulphonylurea.
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Table 4a: Adjusted Pooled Incidence of Overall, Daytime, Nocturnal and  
Severe Hypoglycaemia
Hypoglycaemia Category  Adjusted Mean Incidence ± SE, %   Difference
     IG+MET vs. IG+SU IG+MET vs. IG+MET+SU IG+SU vs. IG+MET+SU
 IG+MET IG+SU IG+MET+SU Pooled Odds Ratio p value Odds Ratio p value Odds Ratio p value
n 634 906 1,297 2,837 (95 % CI)  (95 % CI)  (95 % CI) 
Overall,a PG <3.9 mmol/l 37.0±3.0 52.0±4.4 50.7±2.6 46.5±1.4 0.54 0.005 0.57 0.001 1.06 0.832  
     (0.35–0.83)  (0.41–0.81)  (0.64–1.75) 
Overall,a PG <3.1 mmol/l 16.3±2.3 30.1±4.5 34.1±2.7 26.0±1.3 0.45 0.006 0.38 <0.001 0.83 0.554  
     (0.26–0.80)  (0.25–0.57)  (0.45–1.54) 
Overall,a PG <2.8 mmol/l 11.8±2.0 15.8±3.6 20.7±2.4 15.8±1.1 0.71 0.326 0.51 0.007 0.72 0.392  
     (0.36–1.40)  (0.32–0.83)  (0.34–1.53) 
Daytime,a PG <3.9 mmol/l 30.8±2.9 46.3±4.5 45.0±2.6 40.5±1.4 0.52 0.004 0.55 <0.001 1.05 0.843  
     (0.33–0.81)  (0.38–0.78)  (0.63–1.76) 
Daytime,a PG <3.1 mmol/l 11.8±2.0 23.8±4.3 27.2±2.6 20.0±1.2 0.43 0.008 0.36 <0.001 0.83 0.600  
     (0.23–0.80)  (0.22–0.57)  (0.42–1.64) 
Daytime,a PG <2.8 mmol/l 7.0±1.6 11.9±3.2 15.4±2.2 10.9±0.9 0.56 0.152 0.41 0.004 0.74 0.496  
     (0.25–1.24)  (0.22–0.76)  (0.31–1.77) 
Nocturnal,b PG <3.9 mmol/l 11.5±1.8 15.0±3.5 17.5±2.1 14.5±1.0 0.74 0.384 0.61 0.026 0.83 0.628  
     (0.37–1.47)  (0.40–0.94)  (0.39–1.77) 
Nocturnal,b PG <3.1 mmol/l 4.8±1.2 5.4±2.3 11.3±2.1 6.7±0.7 0.88 0.830 0.40 0.003 0.45 0.189  
     (0.29–2.73)  (0.22–0.72)  (0.13–1.49) 
Nocturnal,b PG <2.8 mmol/l 4.0±1.2 2.2±1.3 6.4±1.6 3.8±0.6 1.88 0.438 0.61 0.178 0.33 0.187  
     (0.38–9.28)  (0.30–1.25)  (0.06–1.72) 
Severe,c (third-party 2.2±0.6 2.2±0.5 1.9±0.4 2.1±0.3 0.99 0.966 1.15 0.683 1.17 0.611  
assistance required)     (0.49–1.99)  (0.59–2.25)  (0.64–2.12) 
Severe,c (third-party assistance 0.4±0.3 0.3±0.2 0.07±0.1 0.2±0.1 1.49 0.638 5.75 0.134 3.86 0.247  
required and PG <2.0 mmol/l)     (0.28–7.80)  (0.58–56.68)  (0.39–38.16) 
 
 
Table 4b: Adjusted Pooled Event Rates of Overall, Daytime, Nocturnal and  
Severe Hypoglycaemia
Hypoglycaemia Category  Adjusted Mean Event Rate ± SE,   Difference
  Events/Patient–Year  IG+MET vs. IG+SU IG+MET vs. IG+MET+SU IG+SU vs. IG+MET+SU
 IG+MET IG+SU IG+MET+SU Pooled Rate Ratio p value Rate Ratio p value Rate Ratio p value
n 634 906 1,297 2,837 (95 % CI)  (95 % CI)  (95 % CI) 
Overall,a PG <3.9 mmol/l 2.05±0.24 5.03±0.84 5.78±0.55 3.90±0.21 0.41 <0.001 0.35 <0.001 0.87 0.572  
     (0.27–0.61)  (0.26–0.48)  (0.54–1.40)
Overall,a PG <3.1 mmol/l 0.64±0.10 1.60±0.34 2.16±0.26 1.30±0.09 0.40 <0.001 0.29 <0.001 0.74 0.331  
     (0.23–0.68)  (0.20–0.44)  (0.40–1.36)
Overall,a PG <2.8 mmol/l 0.34±0.07 0.57±0.15 1.04±0.15 0.59±0.05 0.60 0.144 0.33 <0.001 0.55 0.119  
     (0.31–1.19)  (0.20–0.54)  (0.26–1.17)
Daytime,a PG <3.9 mmol/l 1.55±0.20 3.55±0.65 4.84±0.50 2.99±0.17 0.44 <0.001 0.32 <0.001 0.73 0.244  
     (0.28–0.67)  (0.23–0.45)  (0.44–1.24)
Daytime,a PG <3.1 mmol/l 0.40±0.07 1.00±0.24 1.72±0.23 0.88±0.07 0.40 0.003 0.23) <0.001 0.58 0.116  
     (0.22–0.73)  (0.14–0.37  (0.29–1.15)
Daytime,a PG <2.8 mmol/l 0.21±0.05 0.41±0.13 0.68±0.12 0.39±0.04 0.51 0.096 0.30 <0.001 0.60 0.264  
     (0.23–1.13)  (0.16–0.56)  (0.24–1.47)
Nocturnal,b PG <3.9 mmol/l 0.37±0.07 0.75±0.21 0.79±0.12 0.60±0.05 0.48 0.045 0.46 <0.001 0.96 0.916  
     (0.24–0.98)  (0.29–0.73)  (0.44–2.10)
Nocturnal,b PG <3.1 mmol/l 0.18±0.04 0.25±0.10 0.36±0.07 0.25±0.03 0.71 0.529 0.49 0.013 0.68 0.513  
     (0.25–2.06)  (0.27–0.86)  (0.22–2.15)
Nocturnal,b PG <2.8 mmol/l 0.11±0.04 0.05±0.03 0.24±0.07 0.11±0.02 2.30 0.327 0.44 0.038 0.19 0.067  
     (0.43–12.22)  (0.21–0.95)  (0.03–1.12)
Severe,c (third-party 0.07±0.03 0.10±0.03 0.10±0.03 0.09±0.02 0.71 0.470 0.76 0.565 1.07 0.870  
assistance required)     (0.28–1.81)  (0.29–1.95)  (0.46–2.48)
Severe,d (third-party assistance 0.010± 0.007± 0.002± 0.005± 1.35 0.721 6.05 0.123 4.49 0.193  
required and PG <2.0 mmol/l) 0.006 0.004 0.002 0.002  (0.26–6.90)   (0.62–59.45)  (0.47–43.21) 
Hypoglycaemia incidences and event rates estimated and analysed using negative binomial regression. Plasma glucose (PG) <3.9 mmol/l = <70 mg/dl; PG <3.1 mmol/l = <56 mg/dl; PG 
<2.8 mmol/l = <50 mg/dl; PG <2.0 mmoldl = <36 mg/dl. aAdjusting for baseline body mass index (BMI), duration of diabetes, age, oral antidiabetes drug (OAD) treatment group, study and 
interaction of duration of diabetes and OAD treatment group. bAdjusting for baseline BMI, duration of diabetes, age, OAD treatment group and study. cAdjusting for baseline BMI, duration of 
diabetes, age and OAD treatment group. dAdjusting for duration of diabetes, age and OAD treatment group. IG = insulin glargine; MET = metformin; SE = standard error; SU = sulphonylurea. 
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(see Figure 2). A similar pattern was observed for overall and nocturnal 
hypoglycaemia event rates according to FPG levels achieved at 
endpoint. Modelled hypoglycaemia event rates were consistently higher 
in patients treated with IG+MET+SU and IG+SU compared with IG+MET. 
This was observed regardless of the hypoglycaemia definition and PG 
cutoff used, but increased rates were most marked for overall and 
nocturnal hypoglycaemia event rates with documented PG <3.9 mmol/l.
Glycated Haemoglobin <7.0 % without 
Hypoglycaemia
In the group of patients treated with IG+MET, 36.0 % and 44.9 % achieved 
an HbA1c <7.0  % without overall hypoglycaemia with PG <3.9  mmol/l 
and <3.1 mmol/l, respectively. This rate was higher than that observed in 
patients treated with IG+SU (17.5 % and 24.2 %, respectively) and patients 
treated with IG+MET+SU (17.4  % and 26.5  %, respectively). A similar 
pattern was observed when examining achievement of HbA1c <7.0  % 
without nocturnal hypoglycaemia with PG <3.9 mmol/l and <3.1 mmol/l 
(IG+MET: 48.0  % and 52.9  %, respectively; IG+SU: 27.0  % and 29.4  %, 
respectively; and IG+MET+SU: 35.8 % and 40.0 %, respectively).
Body Weight
Weight increased from baseline to week 24 in all three treatment 
groups (0.8±4.0 kg for IG+MET, 2.8±3.9 kg for IG+SU and 2.0±3.4 kg for 
IG+MET+SU). In the adjusted model, weight gain was significantly lower 
in patients treated with IG+MET compared with IG+SU and IG+MET+SU 
(difference in adjusted change from baseline weight: –1.51 kg, 95 % CI 
–2.13 to –0.88; p<0.0001; and –0.78 kg, 95 % CI –1.30 to –0.25; p=0.0037, 
respectively) and also in patients treated with IG+MET+SU compared 
with IG+SU (–0.73 kg, 95 % CI –1.40 to –0.06; p=0.0329).
Discussion
Hypoglycaemia is a substantial complication in the treatment of type 2 
diabetes. The risk and severity of hypoglycaemia increase with disease 
duration and intensification or duration of insulin treatment.1,18–20 
Severe hypoglycaemia can lead to seizures and coma, and has been 
reported to be associated with an increased risk of macrovascular 
events, microvascular events and all-cause death.21,22 Non-severe 
hypoglycaemia is also associated with a significant reduction in quality 
of life and accounts for a substantial reduction in work productivity.23–25
The current pooled, post hoc analysis of patient-level data from 
15 randomised, controlled, treat-to-target studies of IG with OADs 
illustrates that in this patient population, regimens where a SU is 
utilised are associated with a reduced proportion of patients reaching 
target HbA1c levels and a greater risk of overall, daytime and nocturnal 
hypoglycaemia, along with greater weight gain. The insulin dose at 
endpoint was significantly greater in the IG+MET treatment group, which 
could indicate that a SU limits the amount of insulin added, possibly due 
to the resulting hypoglycaemia and associated weight gain. Rates of 
severe hypoglycaemia associated with IG+MET, IG+SU and IG+MET+SU 
were low (0.07, 0.10 and 0.10 events/patient–year, respectively), and not 
statistically different. Patients treated with IG+SU, who were older, had 
a higher HbA1c and FPG and a lower body weight and BMI at baseline 
than the other two groups, experienced less correction of HbA1c and FPG 
levels, possibly indicating that patients in this treatment group had more 
advanced beta-cell deficiency than in the other two treatment groups. 
Patients in the IG+MET treatment group had a significantly shorter 
duration of diabetes compared with patients who received a SU in their 
treatment regimen. Thus, more favorable efficacy and safety results seen 
in patients treated with MET only may reflect somewhat better beta-cell 
function in the MET only group. Moreover, our analysis indicates that 
treatment with basal insulin soon after MET only failure leads to a better 
glycaemic control compared with the often-delayed insulin treatment in 
patients failing SU or MET+SU therapy. Such patients may need a more 
intensified insulin treatment either by more aggressive up-titration of 
basal insulin dose or earlier addition of a prandial insulin supplement, 
thereby replacing SU medication.
The results of this analysis do, however, support earlier findings 
regarding the overall efficacy of adding IG to prior therapy with MET, SU 
or MET+SU in terms of HbA1c reduction and achievement of an HbA1c 
target level of <7.0 %,5,26–30 and provide important epidemiological data 
on the risk of hypoglycaemia with different OAD regimens, which may be 
a useful reference point for physicians when comparing hypoglycaemia 
rates in other studies. A higher rate of hypoglycaemia with IG+SU and 
IG+MET+SU compared with IG+MET was anticipated based on the mode 
of action of SUs.3 A previous pooled analysis of data from 11 IG clinical 
studies also showed that treatment with IG+MET was associated with a 
higher proportion of patients achieving the HbA1c target of ≤7.0 % (68.1 % 
versus 50.4  % and 56.4  %, respectively; p=0.0006) and significantly 
lower rates of confirmed symptomatic hypoglycaemia (1.81 versus 4.88 
and 7.30 events/patient–year, respectively; p<0.0001) compared with 
IG+SU and IG+MET+SU, respectively.31 The current analysis includes 
more patients in the IG+MET treatment group (n=634) compared with 
the study by Fonseca et al. (n=185), and therefore represents a more 
balanced comparison versus IG+SU and IG+MET+SU (current analysis: 
n=906 and n=1,297; Fonseca study31 n=792 and n=1,084, respectively). In 
addition, the previous study only reported symptomatic hypoglycaemia 
(including confirmed symptomatic and severe symptomatic),31 whereas 
the current analysis provides additional information regarding rates of 
overall, daytime, nocturnal and severe hypoglycaemia.
Comparison of data on hypoglycaemia across clinical studies is 
challenging for several reasons. First, reporting of hypoglycaemia data 
across studies is inconsistent,15 reducing the pool of data available for 
comparison. Variations in study design, such as the insulin titration 
algorithm, FPG targets and the insulin dosing times utilised, can also 
have an effect on the risk of hypoglycaemia. Second, several patient-
related factors are associated with an increased risk of hypoglycaemia 
in type 2 diabetes. These include younger age, lower BMI, previous 
hypoglycaemic events, presence of individual micro- and macrovascular 
complications, duration of diabetes, duration of insulin treatment, type 
of insulin and number of insulin injections.32–37 Finally, and as shown 
in the current study, the type of OAD administered as background 
therapy and the characteristics of the patients administered these 
different combinations can also impact on the risk of hypoglycaemia. 
In agreement with our results, a previous investigation showed that use 
of a SU in addition to MET, rather than MET alone, increased the risk of 
symptomatic hypoglycaemia by up to 88 %.37 Thus, the ability to compare 
the incidences and event rates of hypoglycaemia from this analysis with 
those reported in other published studies is limited and problematic. 
Comparison would only be appropriate if the study methodology, 
the definitions of hypoglycaemia utilised, the study populations and the 
background oral therapy were identical.
This analysis benefits from the inclusion of data from prospective, 
randomised, controlled clinical trials and the large patient population 
evaluated (n=2,837). The large number of centres and geographic 
regions included (Asia, Australia, Eastern and Western Europe and 
North and South America), although liable to introduce variability 
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in the implementation of the treatment regimens, provides an 
advantage in terms of the translatability of the results. Standardised 
protocol-driven titration regimens and treatment targets were used 
in the studies included in the analysis and, in addition, the analysis 
only considered IG administered at bedtime. Derived data were also 
standardised, allowing consistent endpoint definitions to be applied 
across the studies. Furthermore, the patient-level analysis allowed for 
the inclusion of patient-level baseline characteristics as covariates. The 
analysis is, however, limited by the fact that only five IG+MET, six IG+SU 
and nine IG+MET+SU treat-to-target studies were evaluated from 
which relevant patient-level data were available and that the findings 
are limited to IG and therefore not applicable to other basal insulins. 
Although the post hoc nature of the analysis can be considered as a 
limitation, the analyses were conducted using a pre-specified statistical 
analysis plan. In order to fully evaluate the various combinations of oral 
agents and insulin, specifically differences in HbA1c between MET and 
SU, randomised comparative trials are required.
Conclusion
In summary, the results of this pooled, post hoc, analysis of patient-level 
data from treat-to-target randomised trials illustrate that differences in 
glycaemic control, hypoglycaemia risk, weight change and dose can be 
seen in patients with type 2 diabetes, depending on the background 
OAD therapy that is combined with IG. A greater proportion of patients 
treated with IG+MET achieved target glycaemic control and the overall 
risk of hypoglycaemia and weight gain was lower with this regimen 
compared with IG+SU and IG+MET+SU, despite an increased insulin 
dose requirement. n
